Diabetic Retinopathy Screening: Protocol, Findings, and Treatment

Screening Recommendations

  • Type 1 diabetes: Initial dilated exam within 5 years of onset; then annually.
  • Type 2 diabetes: At diagnosis; then annually.
  • Pregnancy: Pre-conception or first trimester; each trimester; 1 year postpartum.
  • High-risk features: More frequent exams (e.g., every 6 months for moderate NPDR).

Screening Methods

  • Dilated fundus examination by ophthalmologist/optometrist (gold standard).
  • Retinal photography (mydriatic/non-mydriatic) with remote grading – validated for screening; not a substitute for comprehensive exam if abnormalities detected.
  • OCT/OCT-A: Detects macular edema, capillary non-perfusion; adjunctive.

Key Findings (ETDRS Classification)

Treatment

  • Anti-VEGF (intravitreal): Aflibercept, ranibizumab, faricimab, bevacizumab – first-line for DME and PDR.
  • Panretinal photocoagulation (PRP): For high-risk PDR; reduces severe vision loss by 50%.
  • Focal/grid laser: For non-center-involving DME (less used now).
  • Vitrectomy: Non-clearing vitreous hemorrhage, traction detachment.
  • Corticosteroids (intravitreal/implants): Refractory DME; cataract/IOP risks.

Systemic Control

Intensive glycemic control (HbA1c <7%), blood pressure control (<130/80), lipid management (statin), and smoking cessation slow DR progression.

Diabetes - Related Articles

Health Sciences © https://www.222health.com

StageFindings
No DRNo abnormalities
Mild NPDRMicroaneurysms only
Moderate NPDRMicroaneurysms + dot/blot hemorrhages, hard exudates, cotton-wool spots, venous beading
Severe NPDR4-2-1 rule: hemorrhages in 4 quadrants, venous beading in 2+, IRMA in 1+
PDRNeovascularization (NVD, NVE), vitreous/preretinal hemorrhage, traction retinal detachment
DME (any stage)Retinal thickening within 1 disc diameter of fovea (clinically significant macular edema)